2024
DOI: 10.1080/14737140.2024.2373888
|View full text |Cite
|
Sign up to set email alerts
|

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC

Pierre Peterlin,
Esma Saada-Bouzid,
Mor Moskovitz
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 25 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?